Patrick Y Sips

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2031909/publications.pdf

Version: 2024-02-01

59 papers	1,466 citations	430442 18 h-index	329751 37 g-index
69 all docs	69 docs citations	69 times ranked	2069 citing authors

#	Article	IF	Citations
1	Hydrogen Sulfide Improves Survival After Cardiac Arrest and Cardiopulmonary Resuscitation via a Nitric Oxide Synthase 3â€“Dependent Mechanism in Mice. Circulation, 2009, 120, 888-896.	1.6	188
2	Anaphylactic shock depends on PI3K and eNOS-derived NO. Journal of Clinical Investigation, 2006, 116, 2244-2251.	3.9	115
3	Gender-specific hypertension and responsiveness to nitric oxide in sGCÎ±1 knockout mice. Cardiovascular Research, 2008, 79, 179-186.	1.8	107
4	Inhaled Nitric Oxide Improves Outcomes After Successful Cardiopulmonary Resuscitation in Mice. Circulation, 2011, 124, 1645-1653.	1.6	91
5	Zebrafish type I collagen mutants faithfully recapitulate human type I collagenopathies. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8037-E8046.	3.3	77
6	Soluble Guanylate Cyclase-Î±1 Deficiency Selectively Inhibits the Pulmonary Vasodilator Response to Nitric Oxide and Increases the Pulmonary Vascular Remodeling Response to Chronic Hypoxia. Circulation, 2007, 116, 936-943.	1.6	71
7	Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock. FASEB Journal, 2006, 20, 2363-2365.	0.2	65
8	Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice. Nature Communications, 2015, 6, 8482.	5.8	64
9	Protective effects of nitric oxide synthase 3 and soluble guanylate cyclase on the outcome of cardiac arrest and cardiopulmonary resuscitation in mice*. Critical Care Medicine, 2009, 37, 256-262.	0.4	63
10	S-Nitrosylation of Calcium-Handling Proteins in Cardiac Adrenergic Signaling and Hypertrophy. Circulation Research, 2015, 117, 793-803.	2.0	60
11	Functional role of the soluble guanylyl cyclase Î±1 subunit in vascular smooth muscle relaxationâ˜†. Cardiovascular Research, 2007, 76, 149-159.	1.8	45
12	Wars2 is a determinant of angiogenesis. Nature Communications, 2016, 7, 12061.	5.8	45
13	sGCÎ±₁Î²₁attenuates cardiac dysfunction and mortality in murine inflammatory shock models. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H654-H663.	1.5	42
14	Pathophysiology of Hypertension in the Absence of Nitric Oxide/Cyclic GMP Signaling. Current Hypertension Reports, 2013, 15, 47-58.	1.5	41
15	Reduction of cardiomyocyte S-nitrosylation by S-nitrosoglutathione reductase protects against sepsis-induced myocardial depression. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H1134-H1146.	1.5	38
16	New insights into the role of soluble guanylate cyclase in blood pressure regulation. Current Opinion in Nephrology and Hypertension, 2014, 23, 135-142.	1.0	33
17	Genetic modifiers of hypertension in soluble guanylate cyclase Î±1â€“deficient mice. Journal of Clinical Investigation, 2012, 122, 2316-2325.	3.9	28
18	Androgen-sensitive hypertension associated with soluble guanylate cyclase-Î±₁ deficiency is mediated by 20-HETE. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H1790-H1800.	1.5	27

#	Article	IF	Citations
19	Gastric motility in soluble guanylate cyclase Î±₁ knockâ€out mice. Journal of Physiology, 2007, 584, 907-920.	1.3	23
20	A homozygous pathogenic missense variant broadens the phenotypic and mutational spectrum of CREB3L1-related osteogenesis imperfecta. Human Molecular Genetics, 2019, 28, 1801-1809.	1.4	21
21	Bi-allelic premature truncating variants in LTBP1 cause cutis laxa syndrome. American Journal of Human Genetics, 2021, 108, 1095-1114.	2.6	19
22	Involvement of soluble guanylate cyclase Î±1 and Î±2, and SKCa channels in NANC relaxation of mouse distal colon. European Journal of Pharmacology, 2008, 589, 251-259.	1.7	18
23	Cisplatin Analogs Confer Protection against Cyanide Poisoning. Cell Chemical Biology, 2017, 24, 565-575.e4.	2.5	17
24	Role of the soluble guanylyl cyclase Î±1-subunit in mice corpus cavernosum smooth muscle relaxation. International Journal of Impotence Research, 2008, 20, 278-284.	1.0	16
25	Role of the soluble guanylyl cyclase Î±1/Î±2 subunits in the relaxant effect of CO and CORM-2 in murine gastric fundus. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 493-502.	1.4	14
26	The alpha1 isoform of soluble guanylate cyclase regulates cardiac contractility but is not required for ischemic preconditioning. Basic Research in Cardiology, 2011, 106, 635-643.	2.5	13
27	Screening drugs for myocardial disease in vivo with zebrafish: an expert update. Expert Opinion on Drug Discovery, 2019, 14, 343-353.	2.5	13
28	Identification of specific metabolic pathways as druggable targets regulating the sensitivity to cyanide poisoning. PLoS ONE, 2018, 13, e0193889.	1.1	12
29	A heart for fibrillin: spatial arrangement in adult wild-type murine myocardial tissue. Histochemistry and Cell Biology, 2018, 150, 271-280.	0.8	11
30	Impact of functional studies on exome sequence variant interpretation in early-onset cardiac conduction system diseases. Cardiovascular Research, 2020, 116, 2116-2130.	1.8	11
31	Sensitivity to Sevoflurane anesthesia is decreased in mice with a congenital deletion of Guanylyl Cyclase-1 alpha. BMC Anesthesiology, 2017, 17, 76.	0.7	10
32	Small intestinal motility in soluble guanylate cyclase Î±1 knockout mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 473-487.	1.4	8
33	Ambulatory Electrocardiographic Monitoring and Ectopic Beat Detection in Conscious Mice. Sensors, 2020, 20, 3867.	2.1	6
34	Corrosion casting of the cardiovascular structure in adult zebrafish for analysis by scanning electron microscopy and Xâ€ray microtomography. Journal of Veterinary Medicine Series C: Anatomia Histologia Embryologia, 2020, 49, 635-642.	0.3	6
35	An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome. Journal of Experimental Pharmacology, 2021, Volume 13, 755-779.	1.5	5
36	Poly (A)-specific ribonuclease (PARN): More than just â€œmRNA stock clearingâ€• Life Sciences, 2021, 285, 119953.	2.0	5

#	Article	IF	Citations
37	Targeting the NO â€“ cGMP pathway: phenotyping of NO-insensitive sGCbeta1 H105F knockin mice. BMC Pharmacology, 2007, 7, .	0.4	4
38	Genetic modification of hypertension by sGCÎ±1. Trends in Cardiovascular Medicine, 2013, 23, 312-318.	2.3	4
39	MEK1/2 Inhibition in Murine Heart and Aorta After Oral Administration of Refametinib Supplemented Drinking Water. Frontiers in Pharmacology, 2020, 11, 1336.	1.6	4
40	Gender-Specific Modulation of the Response to Arterial Injury by Soluble Guanylate Cyclase Î±1. Open Cardiovascular Medicine Journal, 2009, 3, 98-104.	0.6	4
41	Clinical and Molecular Delineation of Cutis Laxa Syndromes: Paradigms for Elastic Fiber Homeostasis. Advances in Experimental Medicine and Biology, 2021, 1348, 273-309.	0.8	4
42	Glyoxylate protects against cyanide toxicity through metabolic modulation. Scientific Reports, 2022, 12, 4982.	1.6	4
43	Phenotypes of sGC mutant mice in basic conditions, disease and shock. BMC Pharmacology, 2009, 9, .	0.4	3
44	Spontaneous Right Ventricular Pseudoaneurysms and Increased Arrhythmogenicity in a Mouse Model of Marfan Syndrome. International Journal of Molecular Sciences, 2020, 21, 7024.	1.8	3
45	Loss of zebrafish atp6v1e1b, encoding a subunit of vacuolar ATPase, recapitulates human ARCL type 2C syndrome and identifies multiple pathobiological signatures. PLoS Genetics, 2021, 17, e1009603.	1.5	3
46	Phenotypic and Molecular Heterogeneity in Mandibulofacial Dysostoses: A Case Series From India. Cleft Palate-Craniofacial Journal, 2022, 59, 1346-1351.	0.5	3
47	NO-mediated vascular smooth muscle relaxation in sGCÎ±1 knock-out mice. BMC Pharmacology, 2005, 5, P41.	0.4	1
48	Genetic modifiers of hypertension in soluble guanylate cyclase Î±1â€“deficient mice. Journal of Clinical Investigation, 2012, 122, 3024-3024.	3.9	1
49	NO-induced motility effects in distal colon of sGCÎ±1 knockout mice. BMC Pharmacology, 2005, 5, P14.	0.4	0
50	Gender-specific hypertension in mice deficient in the alpha1 subunit of soluble guanylate cyclase. BMC Pharmacology, 2005, 5, P52.	0.4	0
51	Lessons from soluble guanylate cyclase alpha1 knockouts. BMC Pharmacology, 2005, 5, S36.	0.4	0
52	Transgenic mice with a NO-insensitive soluble guanylate cyclase. BMC Pharmacology, 2007, 7, .	0.4	0
53	O54. Targeting the NO-cGMP pathway: Phenotyping of NO-insensitive sGCÎ²1 H105F knockin mice. Nitric Oxide - Biology and Chemistry, 2008, 19, 32.	1.2	0
54	O55. Gender-specific hypertension and reaction to NO stimulation in sGCÎ±1â^'/â^' mice. Nitric Oxide - Biology and Chemistry, 2008, 19, 32.	1.2	0

#	Article	IF	Citations
55	sGCÎ±1Î²1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models. BMC Pharmacology, 2009, 9, .	0.4	0
56	Genetic mapping of a modifier locus affecting hypertension in soluble guanylate cyclase Î±1 deficient mice. BMC Pharmacology, 2011, 11, .	0.4	0
57	Identification of renin signaling as a blood pressure modifying mechanism in soluble guanylate cyclase Î±1-deficient mice. Nitric Oxide - Biology and Chemistry, 2012, 27, S25-S26.	1.2	0
58	Androgen-sensitive hypertension associated with soluble guanylate cyclase alpha1 deficiency is mediated by 20-HETE. BMC Pharmacology & Toxicology, 2015, 16, .	1.0	0
59	Protein Sâ€nitrosylation regulates Ca2+ handling and myofilament Ca2+ sensitivity in betaâ€adrenergic signaling. FASEB Journal, 2013, 27, 921.5.	0.2	0